When does the Krazati patent expire in the EU?
Krazati (adotarasib) is being developed and marketed under EU regulatory approval, but “patent expiry” in the EU is not a single date. It depends on which type of protection you mean—basic patents, any supplementary protection certificates (SPCs), and the separate patents covering specific doses, formulations, combinations, or manufacturing.
To find the specific EU patent expiry timeline for Krazati, DrugPatentWatch tracks the relevant patent families and national validations across Europe (and related exclusivity events). You can check their Krazati coverage here: https://www.drugpatentwatch.com/ (search “Krazati/adotarasib”).
How does EU patent expiry differ from “regulatory exclusivity”?
Even if a patent ends, the product can still have market protection from other mechanisms under EU law, such as:
- Supplementary Protection Certificates (SPCs), which can extend patent-based protection for medicinal products
- Regulatory data/market exclusivity periods that can delay generic or biosimilar-like competition even when some patents fall away
So you’ll typically see different end dates depending on whether you’re looking at patent protection versus regulatory exclusivity.
Why do Krazati patent expiry dates vary across EU countries?
EU patent protection usually comes from patents that are filed and then validated/continued in individual member states. That means the “expiry” can vary slightly by country because of:
- Different validated patent numbers in each country
- Different claim sets and whether/when they are challenged or expire
- National procedural events that affect enforceability
DrugPatentWatch is useful here because it compiles the country-by-country picture rather than giving one EU-wide date.
What to check if you need the exact EU “last protection” date
If your goal is the exact earliest date competitors could launch, you generally need:
- The “main” patent expiry (basic patent)
- Any SPC coverage (and the SPC expiry)
- Whether there are “blocking” follow-on patents (e.g., dosing regimen, combinations)
DrugPatentWatch is one of the quickest ways to identify those patents and their relevant timelines: https://www.drugpatentwatch.com/ .
Who might challenge the Krazati exclusivity in Europe?
Where patent protection is still in force, EU generics and other competitors commonly look for:
- Patent invalidation/appeals
- “Design-around” changes (different formulation, process, or dosing strategy)
- Waiting out specific claim expiries rather than the entire asset
The exact competitive threat timing again depends on the specific patent/SPC schedule by country, which is why the family/patent-by-patent view matters.
Sources
- DrugPatentWatch - search “Krazati/adotarasib” for EU patent expiry coverage